NO20065339L - Cholinesteraseinhibitorer i liposomer og deres fremstilling og anvendelse - Google Patents

Cholinesteraseinhibitorer i liposomer og deres fremstilling og anvendelse

Info

Publication number
NO20065339L
NO20065339L NO20065339A NO20065339A NO20065339L NO 20065339 L NO20065339 L NO 20065339L NO 20065339 A NO20065339 A NO 20065339A NO 20065339 A NO20065339 A NO 20065339A NO 20065339 L NO20065339 L NO 20065339L
Authority
NO
Norway
Prior art keywords
liposomes
topical
active ingredient
cutaneous
relates
Prior art date
Application number
NO20065339A
Other languages
English (en)
Norwegian (no)
Inventor
Eberhard Pirich
Werner Frantsits
Angelika Bodenteich
Josef Bockmann
Andreas Wagner
Karola Vorauer-Uhl
Original Assignee
Sanochemia Pharmazeutika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag filed Critical Sanochemia Pharmazeutika Ag
Publication of NO20065339L publication Critical patent/NO20065339L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20065339A 2004-04-22 2006-11-21 Cholinesteraseinhibitorer i liposomer og deres fremstilling og anvendelse NO20065339L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0069604A AT500143A1 (de) 2004-04-22 2004-04-22 Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
PCT/AT2005/000138 WO2005102268A2 (de) 2004-04-22 2005-04-21 Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung

Publications (1)

Publication Number Publication Date
NO20065339L true NO20065339L (no) 2007-01-09

Family

ID=35197479

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065339A NO20065339L (no) 2004-04-22 2006-11-21 Cholinesteraseinhibitorer i liposomer og deres fremstilling og anvendelse

Country Status (10)

Country Link
US (1) US20080031935A1 (zh)
EP (1) EP1737426A2 (zh)
JP (1) JP2007533666A (zh)
CN (1) CN1946377A (zh)
AT (1) AT500143A1 (zh)
AU (1) AU2005235430A1 (zh)
CA (1) CA2563861A1 (zh)
NO (1) NO20065339L (zh)
RU (1) RU2006141254A (zh)
WO (1) WO2005102268A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086698A2 (en) * 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
EP3056200B1 (en) 2005-05-23 2023-09-06 President and Fellows of Harvard College Huperzine for use in treating seizure
DE102006056783A1 (de) * 2006-12-01 2008-06-05 Lts Lohmann Therapie-Systeme Ag Zubereitung zur transdermalen Verabreichung von Galanthamin
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
RU2571077C2 (ru) * 2011-03-25 2015-12-20 Терумо Кабусики Кайся Липосомальная композиция длительного действия с контролируемым высвобождением и способ ее получения
JP5848511B2 (ja) * 2011-03-29 2016-01-27 株式会社コーセー リポソーム組成物、並びにそれを用いた化粧料、皮膚外用剤及びその製造方法
CN102178680B (zh) * 2011-04-24 2012-09-05 浙江现代中药与天然药物研究院有限公司 一种长效高含量的石杉碱甲贴片及其制备方法
US9685730B2 (en) 2014-09-12 2017-06-20 Steelcase Inc. Floor power distribution system
GB2561157A (en) * 2017-03-27 2018-10-10 Univ Oxford Innovation Ltd Compartmentalised gel matrix and method of production
KR102046355B1 (ko) * 2018-02-08 2019-11-19 국방과학연구소 피하주사용 피소스티그민의 서방출성 리포좀 제제 및 이의 제조 방법
EP3826615A4 (en) * 2018-07-24 2022-05-04 Taiwan Liposome Company, Ltd. DELAYED RELEASE PHARMACEUTICAL COMPOSITIONS WITH A THERAPEUTIC AGENT FOR THE TREATMENT OF DEMENTIA AND USES THEREOF
US12005142B2 (en) * 2018-08-02 2024-06-11 Taiwan Liposome Co., Ltd. Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
US20210308051A1 (en) * 2018-08-08 2021-10-07 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB942200A (en) * 1959-03-02 1963-11-20 Chimiko Pharmazevtitschen Zd A method of obtaining galanthamine hydrobromide
EP0152379A3 (de) * 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
US4937078A (en) * 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
DE3843239C1 (zh) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5064655A (en) * 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
JPH04505616A (ja) * 1989-05-15 1992-10-01 ザ　リポソーム　カンパニー，インコーポレイテッド プロトン勾配によるリポソームへの薬剤の蓄積
IT1254464B (it) * 1992-02-17 1995-09-25 Enzo Anaclio Uso di sostanze parasimpaticomimetiche dirette per la terapia del dolore.
CA2097163C (en) * 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
IT1304904B1 (it) * 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
AU1490401A (en) * 1999-11-16 2001-05-30 George F. El Khoury Topical application of muscarinic analgesic drugs such as neostigmine
ES2215885T3 (es) * 2000-03-31 2004-10-16 Sanochemia Pharmazeutika Aktiengesellschaft Nuevos derivados y analogos de la galantamina.
EP1285656A4 (en) * 2000-04-13 2006-07-12 Eisai Co Ltd ACETYLCHOLINESTERASE HEMMER CONTAINING 1-BENZYLPYRIDINIUM SALT
WO2001098271A1 (fr) * 2000-06-21 2001-12-27 Eisai Co., Ltd. Compose piperidine 4-substitue
EP1203614A1 (de) * 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
DE60223904T2 (de) * 2001-01-26 2008-11-27 Btg International Ltd. Benzylaminanalogen
US6951655B2 (en) * 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20030235609A1 (en) * 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid

Also Published As

Publication number Publication date
RU2006141254A (ru) 2008-05-27
US20080031935A1 (en) 2008-02-07
AT500143A1 (de) 2005-11-15
JP2007533666A (ja) 2007-11-22
CA2563861A1 (en) 2005-11-03
WO2005102268A2 (de) 2005-11-03
AU2005235430A1 (en) 2005-11-03
WO2005102268A3 (de) 2006-04-06
CN1946377A (zh) 2007-04-11
EP1737426A2 (de) 2007-01-03

Similar Documents

Publication Publication Date Title
NO20065339L (no) Cholinesteraseinhibitorer i liposomer og deres fremstilling og anvendelse
WO2009011412A3 (en) Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
NO20062703L (no) Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
CY1109519T1 (el) Κεκορεσμενες και ακορεστες 3-πυριδυλο-βενζοκυκλοαλκυλομεθυλαμινες για τη θεραπεια πονων, καταθλιψεων και καταστασεων φοβου
EP1201239A4 (en) CYCLIC AMINES AS CCR3 ANTAGONISTS
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
NO20092018L (no) Fremgangsmater for a behandle depresjon
DK1893237T3 (da) Farmaceutisk sammensætning, der omfatter en organopolysiloxan ela-stomer og et solubiliseret aktivt stof
PT1414467E (pt) Tratamento topico da mastalgia
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
WO2002043731A3 (en) Treatments for neurogenetic disorders, impulse control disorders, and wound healing
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
ATE395061T1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer
NO20070136L (no) Antitumor effekt potentiator, antitumor preparering og fremgangsmater for cancerterapi
IL190850A (en) Use of Artemisinin and Derivatives to Prepare a Pharmacist and Insulin Composition Containing Local Compositions Containing Them
AR006578A1 (es) Composiciones fungicidas que comprenden ciprodinil con miclobutanil o iprodiona y que tienen accion sinergica contra las enfermedades de plantas y unmetodo de proteccion contra las enfermedades
NO20055254L (no) Farmasoytisk kombinasjon for behandling av spastisitet og/eller smerte

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application